Journal Article

Effectiveness and Safety of Eliglustat Treatment in Gaucher Disease: Real-life Unicentric Experience

Grasso, Stephanie, Gullo, Lara, Calafiore, Valeria, Markovic, Uros, Fazio, Manlio, Di Raimondo, Francesco, Giuffrida, Gaetano, Riccobene, Carla, Duminuco, Andrea

2023

Overview

The therapy and management of Gaucher disease (GD) have radically changed with the use of substrate reduction therapy, of which eliglustat is the most widely known drug, allowing it to overcome the limits of enzyme replacement therapy (ERT). The rarity of GD and the limited use of eliglustat outside clinical trials require further study of its strengths and weaknesses. In this study, we evaluated the effectiveness and safety of eliglustat in a cohort of 12 patients with GD followed up in our center, reporting a reduction in both chitotriosidase (394.3 vs 181.1 nmol/h/mL, P = 0.027) and glucosylsphingosine values (45.1 vs 18.9 ng/mL, P <0.001) after at least 12 months of therapy compared with baseline, regardless of patient demographic characteristics and GD characteristics. There were no drug-related serious adverse effects and no drug-related cardiac events. Most adverse events were mild and transient, mainly dyspepsia and abdominal pain. Of interest, we reported an absence of statistical difference in terms of response regarding glucosylsphingosine reduction in relation to naive or prior exposure to ERT (P = 0.296), which was confirmed also when patients were placed in naive and treated groups for <5 vs >5 years (P = 0.667). The use of eliglustat immediately after diagnosis may guarantee the best treatment for patients with milder phenotypes or with aggressive disease after an initial stabilization with ERT compared with ERT, which cannot adequately remove the disease burden despite the apparent response, thus potentially reducing future complications caused by substrate deposits.

• Publisher: Elsevier Inc,Elsevier Limited
• Subject: Blood / Bone marrow / Chitotriosidase / Clinical trials / Dyspepsia / Eliglustat / Enzyme Replacement Therapy - adverse effects / Enzymes / Gaucher disease / Gaucher Disease - diagnosis / Gaucher Disease - drug therapy / Gaucher's disease / Gender / Glucosylsphingosine / Hemoglobin / Humans / Internal Medicine / Liver / Mutation / Patients / Phenotypes / Psychosine - therapeutic use / Pyrrolidines - therapeutic use / Quality of life / Software / Spleen